Tuvdenjamts, Baljinnyam
Loading...
Товч нэр
Tuvdenjamts, Baljinnyam
Бүтэн нэр
Tuvdenjamts Baljinnyam
Латин нэр
Tuvdenjamts Baljinnyam
Албан тушаал
Судлаач
3 results
Now showing 1 - 3 of 3
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Regulating Action of in Vitro Hepatitis C Virus Infection on Interferon-Induced Interferon Stimulating Genes in Murine Macrophages(Mongolian National University of Medical Sciences, 2018-03-25); ;Batkhishig Munkhjargal; ; Objectives: The objective of this study was to determine the in vitro regulating effect of Hepatitis C virus (HCV) infection on interferon stimulating genes (ISGs) stimulated by IFN-ү and Imiquimod (TLR7 ligand) on murine macrophages. iNOS and STAT1 were measured by RT-PCR, and immunoblotting (IB). Nitric oxide production was measured by Griess Reagent Assay. Objectives: The objective of this study was to determine the in vitro regulating effect of Hepatitis C virus (HCV) infection on interferon stimulating genes (ISGs) stimulated by IFN-ү and Imiquimod (TLR7 ligand) on murine macrophages. iNOS and STAT1 were measured by RT-PCR, and immunoblotting (IB). Nitric oxide production was measured by Griess Reagent Assay. Results: HCV inhibits IFN induced iNOS mRNA and also protein expression. HCV significantly reduced IFN-ү induced ISGs (iNOS mRNA, iNOS protein, s727-STAT1, tyr701- STAT1). Conclusion: These results indicate that in vitro hepatitis C virus infection is involved in the regulation of IFN-ү induced ISGs in the levels of gene and protein expression of iNOS and STAT1 transcription factors.: HCV inhibits IFN induced iNOS mRNA and also protein expression. HCV significantly reduced IFN-ү induced ISGs (iNOS mRNA, iNOS protein, s727-STAT1, tyr701- STAT1). Conclusion: These results indicate that in vitro hepatitis C virus infection is involved in the regulation of IFN-ү induced ISGs in the levels of gene and protein expression of iNOS and STAT1 transcription factors. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Determining Gastric Cancer-Related Risk Factors in Mongolian Population Using ABC(D) Method: A Matched Case-Control Study.(2022-03); ;Lonjid, Tulgaa ;Badamjav, Tegshjargal; Scopus© Citations 5 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Diagnostic performances of pepsinogens and gastrin-17 for atrophic gastritis and gastric cancer in Mongolian subjects(2022); ;Amarbayasgalan, Dashmaa ;Batsaikhan, Batbold ;Badamjav, TegshjargalIn Mongolia, gastric cancer morbidity and mortality are high, and more than 80 percent of cases are diagnosed at an advanced stage. This study aimed to evaluate pepsinogens (PGIs) and gastrin-17 (G-17) levels and to determine the diagnostic performances for gastric cancer and chronic atrophic gastritis among Mongolian individuals. We enrolled a total of 120 subjects, including gastric cancer (40), atrophic gastritis (40), and healthy control (40), matched by age (±2) and sex. Pepsinogen I (PGI), Pepsinogen II (PGII), G-17, and H. pylori IgG levels were measured using GastroPanel ELISA kit (Biohit, Helsinki, Finland). Also, PGI to PGII ratio (PGR) was calculated. For atrophic gastritis, when the optimal cut-off value of PGI was ≤75.07 ng/ml, the sensitivity and specificity were 75% and 50%, respectively; when the optimal cut-off value of PGR was ≤6.25, sensitivity and specificity were 85% and 44.7%, respectively. For gastric cancer, when the optimal cut-off value of PGI was ≤35.25 ng/ml, the sensitivity and specificity were 47.2% and 86.8%, respectively; when the optimal cut-off value of PGR was ≤5.27, sensitivity and specificity were 75% and 60.5%, respectively. Combinations of biomarkers with risk factors could improve diagnostic accuracy (AUC for atrophic gastritis 74.8, 95% CI 64.0-85.7, p<0.001; AUC for gastric cancer 75.5, 95% CI 64.2-86.8, p<0.001). PGI, PGR biomarkers combined with the risk of age, family history of gastric cancer, and previous gastric disease could not be an alternative test for upper endoscopy but might be a supportive method which is identifying individuals at medium- and high risk of gastric cancer and precancerous lesions who may need upper endoscopy.Scopus© Citations 15
